PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer

Annals of Oncology

Volumn 28, Issue 4, 2017, Pages 882-889

  Tsao, M S ^a,b   Le Teuff, G ^c,d   Shepherd, F A ^b,e   Landais, C ^c   Hainaut, P ^f   Filipits, M ^g   Pirker, R ^g   Le Chevalier, T ^c   Graziano, S ^h   Kratze, R ⁱ   Soria, J C ^c   Pignon, J P ^c,d   Seymour, L ^j   Brambilla, E ^f,k  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIV GRENOBLE ALPES   (France)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^j QUEEN S UNIVERSITY   (Canada)

^k GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Checkpoint inhibitors; E1L3N antibody; Immune cells; Immunotherapy; LACE Bio; PD L1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM COMPLEX; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; EGFR GENE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LUNG RESECTION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; MORTALITY; PROGNOSIS;

ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PROGNOSIS;

EID: 85019108563     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx003     Document Type: Article

References (21)

1. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135.
2. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
3. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
4. Herbst RS, Baas P, Kim D-W et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550.
5. Reck M, Rodríguez D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-1833.
6. Fehrenbacher L, Spira A, Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-1846.
7. Champiat S, Ileana E, Giaccone G et al. Incorporating immunecheckpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol 2014; 9: 144-153.
8. Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 2014; 20: 2831-2837.
9. Kodumudi KN, Woan K, Gilvary DL et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16: 4583-4594.
10. Langer CJ, Gadgeel SM, Borghaei H et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous nonsmall-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17: 1497-1508.
11. Tsao MS, Marguet S, Le Teuff G et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients. J Clin Oncol 2015; 33: 3439-3446.
12. Brambilla E, Le Teuff G, Marguet S et al. Prognostic effect of tumorlymphocytic infiltration in resectable non-small cell lung cancer. J Clin Oncol 2016; 34: 1223-1230.
13. Soria JC, Brambilla E, Le Teuff G et al. A pooled analysis to the prognosis and predictive value of EGFR mutation on survival in patients with KRAS wild-type lung adenocarcinoma. J Thorac Oncol 2011; 6(Suppl 6): S617.
14. Shepherd FA, Domerg C, Hainaut P et al. A pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early stage resected non-small cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013; 31: 2173-2181.
15. Ma X, Le Teuff G, Lacas B et al. Prognostic and predictive effect of TP53 mutations in non-small cell lung cancer patients from adjuvant cisplatinbased therapy randomized trials: a LACE-bio pooled analysis. J Thorac Oncol 2016; 11: 850-861.
16. McLaughlin JF, Schalper K, Carvajal-Hausdorf DE et al. Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). J Clin Oncol 2014; 32(Suppl): 5s (abstr 8064).
17. Kerr KM, Tsao M-S, Nicholson AG et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 2015; 10: 985-989.
18. Rimm D, Han G, Taube JM et al. A prospective, multi-institutional assessment of four assays for PD-L1 expression in NSCLC by immunohistochemistry. J Thorac Oncol 2016; 11: S249.
19. Yoshizawa A, Motoi N, Riely GJ et al. Impact of proposed IASLC/ATS/ ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24: 653-664.
20. Cooper WA, Tran T, Vilain RE et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015; 89: 181-188.
21. Calles A, Liao X, Sholl LM et al. Expression of PD-1 and its ligands, PDL1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer. J Thorac Oncol 2015; 10: 1726-1735.